Purpose: We aimed to evaluate the effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degenerations (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Procedures: 246 eyes from 242 patients (tAMD: 139, PCV: 107 eyes) were recruited. Gender, age, best-corrected visual acuity (BCVA) before treatment, greatest linear dimension before treatment, lesion phenotype and PDT frequency were evaluated for predicting the BCVA at 12 months after PDT using stepwise multiple regression analyses. Additionally, 125 eyes with tAMD and 97 eyes with PCV followed up for more than 12 months after the final PDT were compared for the recurrence period. Results: In the stepwise analysis, a younger age, better pretreatment BCVA, lower PDT frequency, lesions with PCV and a smaller pretreatment greatest linear dimension were all significantly beneficial for a better BCVA at 12 months after PDT. PCV showed a significantly lower PDT frequency and greater improvement in the BCVA than tAMD. The recurrence period of PCV was significantly later than that of tAMD. Conclusions: The phenotype of AMD is significantly correlated with its prognosis after PDT. PCV showed a significantly better response to PDT in terms of BCVA improvement and effect durability.

Keywords:
Photodynamic therapy, Age-related macular degeneration, Polypoidal choroidal vasculopathy
1.
Segato T, Midena E, Blarzino MC: Age-related macular degeneration. Aging (Milano) 1993;5:165–176.
2.
Leibowitz HM, Krueger DE, Maunder LR, et al: The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2,631 adults, 1973–1975. Surv Ophthalmol 1980;24 (suppl):335–610.
3.
Yannuzzi LA, Sorenson J, Spaide RF, et al: Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10:1–8.
4.
Uyama M, Matsubara T, Fukushima I, et al: Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999;117:1035–1042.
5.
Yannuzzi LA, Ciardella A, Spaide RF, et al: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478–485.
6.
Spaide RF, Yannuzzi LA, Slakter JS, et al: Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100–110.
7.
Ciardella AP, Donsoff IM, Huang SJ, et al: Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49:25–37.
8.
Maruko I, Iida T, Saito M, Nagayama D, Saito K: Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15–22.
9.
Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N: Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416–434.
10.
Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C: Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244:1224–1232.
11.
Krebs I, Krepler K, Stolba U, Goll A, Binder S: Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol 2008;246:237–243.
12.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: 1-year results of 2 randomized clinical trials: TAP report 1. Arch Ophthalmol 1999;117:1329–1345.
13.
Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541–560.
14.
Verteporfin in Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial: VIP report No 1. Ophthalmology 2001;108:841–852.
15.
Blinder KJ, Blumenkranz MS, Bressler NM, et al: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial: VIP report No 3. Ophthalmology 2003;110:667–673.
16.
Spaide RF, Martin ML, Slakter J, et al: Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134:62–68.
17.
Chan WM, Lam DS, Wong TH, et al: Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year result of an uncontrolled, prospective case series. Ophthalmology 2003;110:2395–2402.
18.
Chan WM, Lam DSC, Lai TYY, et al: Photodynamic therapy with verteprofin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology 2004;111:1576–1584.
19.
Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R: Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007;51:270–277.
20.
Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y: One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141–146.
21.
Bessler NM; Vam Study Writing Committee: Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina 2004;24:512–520.
22.
Japanese Age-Related Macular Degeneration Trial (JAT) Study Group: Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049–1061.
23.
Potter MJ, Szabo SM: Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 2007;91:753–756.
24.
Nakajima M, Yuzawa M, Shimada H, Mori R: Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2004;48:249–255.
25.
Kondo N, Honda S, Ishibashi K, Tsukahara Y, Negi A: Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal vasculopathy. Invest Ophthalmol Vis Sci 2008;49:1101–1105.
26.
Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627–637.
27.
Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M: Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration: 6- and 9-month results. Eye 2008;22:82–86.
28.
Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y: Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70–73.
29.
Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N: Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17–25.
30.
Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmit AM, Dehghan MH, Moradian S: Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007;7:10.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.